Theravance Biopharma Inc. (NASDAQ: TBPH) announced that its Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE